Should we treat genetic syndromes?

R. G. Rosenfeld, C. K. Buckway

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


With the greater availability of GH due to the development of recombinant human GH, GH therapy has expanded well beyond the original FDA indication for GHD. We examine the NCGS database, comparing data for FDA-approved indications with data for 'other' conditions to see whether such expanded use is warranted. Although statistical analyses are of questionable validity because of the small size of some subpopulations and other factors discussed herein, certain trends emerge from the data captured by NCGS. We conclude that many clinical syndromes characterized by short stature are responsive to GH, at least in the short term. For many such syndromes, responsiveness is of the same magnitude as that seen in Turner's syndrome and, occasionally, GHD. If responsiveness to GH is the most important criterion for GH therapy, these 'other' conditions warrant an open-minded, prospective evaluation.

Original languageEnglish (US)
Pages (from-to)971-981
Number of pages11
JournalJournal of Pediatric Endocrinology and Metabolism
Issue numberSUPPL. 2
StatePublished - 2000


  • Genetic syndromes
  • Growth hormone
  • Short stature

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology


Dive into the research topics of 'Should we treat genetic syndromes?'. Together they form a unique fingerprint.

Cite this